190 related articles for article (PubMed ID: 25894564)
1. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
[TBL] [Abstract][Full Text] [Related]
2. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Murai K; Kowata S; Shimoyama T; Yashima-Abo A; Fujishima Y; Ito S; Ishida Y
Eur J Haematol; 2014 Oct; 93(4):290-6. PubMed ID: 24750292
[TBL] [Abstract][Full Text] [Related]
6. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
Nomura M; Ohuchi M; Sakamoto Y; Kudo K; Yaku K; Soga T; Sugiura Y; Morita M; Hayashi K; Miyahara S; Sato T; Yamashita Y; Ito S; Kikuchi N; Sato I; Saito R; Yaegashi N; Fukuhara T; Yamada H; Shima H; Nakayama KI; Hirao A; Kawasaki K; Arai Y; Akamatsu S; Tanuma SI; Sato T; Nakagawa T; Tanuma N
Nat Commun; 2023 Dec; 14(1):8095. PubMed ID: 38092728
[TBL] [Abstract][Full Text] [Related]
7. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S
J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612
[TBL] [Abstract][Full Text] [Related]
9. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
Shames DS; Elkins K; Walter K; Holcomb T; Du P; Mohl D; Xiao Y; Pham T; Haverty PM; Liederer B; Liang X; Yauch RL; O'Brien T; Bourgon R; Koeppen H; Belmont LD
Clin Cancer Res; 2013 Dec; 19(24):6912-23. PubMed ID: 24097869
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Olesen UH; Hastrup N; Sehested M
APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
[TBL] [Abstract][Full Text] [Related]
11. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs.
Pessina A; Parent-Massin D; Albella B; Van Den Heuvel R; Casati S; Croera C; Malerba I; Sibiril Y; Gomez S; de Smedt A; Gribaldo L
Toxicol In Vitro; 2009 Feb; 23(1):194-200. PubMed ID: 19084588
[TBL] [Abstract][Full Text] [Related]
12. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S
Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529
[TBL] [Abstract][Full Text] [Related]
15. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
[TBL] [Abstract][Full Text] [Related]
16. Physiologic role of TPO in thrombopoiesis.
Miyazaki H
Stem Cells; 1996; 14 Suppl 1():133-8. PubMed ID: 11012213
[TBL] [Abstract][Full Text] [Related]
17. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells.
Tolstikov V; Nikolayev A; Dong S; Zhao G; Kuo MS
PLoS One; 2014; 9(12):e114019. PubMed ID: 25486521
[TBL] [Abstract][Full Text] [Related]
20. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia.
Kurzrock R
Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):9-11. PubMed ID: 11033833
[No Abstract] [Full Text] [Related]
[Next] [New Search]
